A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity ...

The US regulator has cleared Lumakras (sotorasib) in combination with Amgen's anti-EGFR antibody Vectibix (panitumumab) for ...

The US regulator has cleared TROP2-directed ADC datopotamab deruxtecan (Dato-DXd) under the Datroway trade name as a ...

The US regulator has cleared Lumakras (sotorasib) in combination with Amgen's anti-EGFR antibody Vectibix (panitumumab) for ...

Meanwhile, Sage reported failed phase 2 trials of dalzanemdor in Alzheimer's, Parkinson's, and Huntington's disease, and ...

Hospitals should expand and speed up testing of people hospitalised with influenza to see if they are suffering from bird flu ...

The FDA has banned the use of a synthetic red dye used in oral medicines, as well as foods and dietary supplements, more than ...

Generative artificial intelligence (GenAI) player Bioptimus has swelled its coffers with another financing round, raising $41 ...

Continued pricing pressures from governments and patient groups are driving small molecule CDMOs to focus on reducing the ...

The establishment of the ERAS protocols catalyses the changes in the IV treatment settings and highlights the need for a ...

At the top of that list, unsurprisingly, are Novo Nordisk obesity drugs Ozempic, Rybelsus, and Wegovy, all grouped together ...

Mounjaro, like other GLP-1 drugs, carries potential side effects, including nausea, vomiting, dehydration, and hypoglycaemia ...